Claims
- 1-16. canceled.
- 17. A method for treating a disorder of the central nervous system comprising administering to the respiratory tract of a patient in need of treatment a drug for treating said disorder, wherein the drug is administered in a dose that is at least about two times less than that required by oral administration and wherein delivery is to the pulmonary system.
- 18. The method of claim 17 wherein the dose is between about two times and about five times less than that required by oral administration.
- 19. The method of claim 17 wherein the dose is between about two times and about ten times less than that required by oral administration.
- 20. The method of claim 17 wherein delivery is to the alveoli region of the pulmonary system.
- 21. The method of claim 17 wherein administering is for rescue therapy.
- 22. The method of claim 17 wherein administering is during ongoing treatment.
- 23. The method of claim 17 wherein the disorder is Parkinson's disease.
- 24. The method of claim 17 wherein the patient in need of treatment is suffering from diseases selected from the group consisting of migraine, anxiety, psychosis, depression, bipolar disorder, obsessive compulsive disorder, convulsions, seizures, epilepsy, Alzheimer's, attention deficit hyperactivity disorder and migraines.
- 25. The method of claim 17 wherein the drug is present in dry powder particles.
- 26. The method of claim 25 wherein the drug is present in the dry powder particles in an amount of at least 20 weight percent.
- 27. The method of claim 25 wherein the drug is present in the dry powder particles in an amount of at least 40 weight percent.
- 28. The method of claim 25 wherein the drug is present in the dry powder particles in an amount of at least 50 weight percent.
- 29. The method of claim 25 wherein the particles have a tap density of less than about 0.4 g/cm3.
- 30. The method of claim 25 wherein the particles have a mass median aerodynamic diameter of less than about 5 microns.
- 31. The method of claim 25 wherein the particles have a mass median geometric diameter greater than about 5 microns.
- 32. The method of claim 25 wherein the particles have a mass median aerodynamic diameter of less than about 3 microns.
- 33. The method of claim 25 wherein the particles include a phospholipid.
- 34. The method of claim 25 wherein the particles include citrate and a multivalent salt.
- 35. The method of claim 25 wherein the particles include an amino acid.
- 36. The method of claim 35 wherein the amino acid is leucine.
- 37. The method of claim 25 wherein the particles are administered via a dry powder inhaler.
- 38. The method of claim 17 further comprising co-administering at least one additional agent.
- 39. A method for treating Parkinson's disease comprising administering to the respiratory tract of a patient in need of treatment or rescue therapy a drug for treating Parkinson's disease wherein the drug is administered in a dose that is at least about two times less than that required by oral administration and wherein delivery is to the pulmonary system.
- 40. The method of claim 39 wherein the drug is levodopa.
- 41. The method of claim 39 wherein the dose is between about two times and about five times less than that required by oral administration.
- 42. The method of claim 39 wherein the dose is between about two times and about ten times less than that required by oral administration.
- 43. The method of claim 39 wherein delivery is to the alveoli region of the pulmonary system.
- 44. The method of claim 39 wherein administering is for rescue therapy.
- 45. The method of claim 39 wherein administering is during ongoing treatment.
- 46. The method of claim 39 wherein the drug is present in dry powder particles.
- 47. The method of claim 46 wherein the drug is present in the dry powder particles in an amount of at least 20 weight percent.
- 48. The method of claim 46 wherein the drug is present in the dry powder particles in an amount of at least 40 weight percent.
- 49. The method of claim 46 wherein the drug is present in the dry powder particles in an amount of at least 50 weight percent.
- 50. The method of claim 46 wherein the particles have a tap density of less than about 0.4 g/cm3.
- 51. The method of claim 46 wherein the particles have a mass median aerodynamic diameter of less than about 5 microns.
- 52. The method of claim 46 wherein the particles have a mass median geometric diameter greater than about 5 microns.
- 53. The method of claim 46 wherein the particles have a mass median aerodynamic diameter of less than about 3 microns.
- 54. The method of claim 46 wherein the particles include a phospholipid.
- 55. The method of claim 46 wherein the particles include citrate and a multivalent salt.
- 56. The method of claim 46 wherein the particles include an amino acid.
- 57. The method of claim 46 wherein the amino acid is leucine.
- 58. The method of claim 46 wherein the particles are administered via a dry powder inhaler.
- 59. The method of claim 58 wherein the dry powder inhaler is a single dose breath activated dry powder inhaler.
- 60. The method of claim 39 further comprising co-administering at least one additional agent.
- 61. A method for treating a disorder of the central nervous system comprising administering to the respiratory tract of a patient in need of treatment a drug for treating said disorder, wherein the drug is administered in a dose that is at least about two times less than that required by administration routes other than intravenous and wherein delivery is to the pulmonary system.
- 62. A method for treating a disorder of the central nervous system comprising administering to the respiratory tract of a patient in need of treatment or rescue therapy ketoprofen, wherein ketoprofen is administered in a dose that is at least about two times less than that required by oral administration and wherein delivery is to the pulmonary system.
- 63. A method for treating a disorder of the central nervous system comprising administering to the respiratory tract of a patient in need of rescue therapy a benzodiazepine drug, wherein the benzodiazepine drug is administered in a dose that is at least about two times less than that required by oral administration and wherein delivery is to the pulmonary system.
- 64. A method of treating a disorder of the central nervous system comprising: administering to the respiratory tract of a patient in need of rescue therapy particles comprising an effective amount of a benzodiazepine drug wherein the particles are delivered to the pulmonary system and the benzodiazepine drug is released in the blood stream of the patient and reaches its site of action within a time sufficiently short to provide said rescue therapy.
- 65. The method of claim 64 wherein the rescue therapy is for a panic attack.
- 66. The method of claim 64 wherein the benzodiazepine drug is present in the particles in an amount ranging from about 1 to about 90 weight percent.
- 67. The method of claim 64 wherein the particles have a tap density less than about 0.4 g/cm3.
- 68. The method of claim 64 wherein the particles have a volume median geometric diameter of between about 5 micrometers and about 30 micrometers.
- 69. The method of claim 64 wherein the particles have an aerodynamic diameter of between about 1 and about 5 microns.
- 70. The method of claim 69 wherein the particles have an aerodynamic diameter of between about 1 and about 3 microns.
- 71. The method of claim 69 wherein the particles have an aerodynamic diameter of between about 3 and about 5 microns.
- 72. The method of claim 64 wherein delivery to the pulmonary system includes delivery to the alveoli.
- 73. The method of claim 64 wherein the particles include a phospholipid.
- 74. The method of claim 73 wherein the phospholipid has a matrix transition temperature which is no higher than the patient's physiological temperature.
- 75. The method of claim 73 wherein the phospholipid is present in the particles in an amount ranging from about 10 to about 99 weight percent.
- 76. The method of claim 64 wherein the particles include a hydrophobic amino acid.
- 77. The method of claim 76 wherein the hydrophobic amino acid is present in the particles in an amount of a least 10% by weight.
- 78. The method of claim 64 wherein the particles include citrate.
- 79. The method of claim 78 wherein the particles further include calcium chloride.
- 80. The method of claim 64 wherein delivery to the pulmonary system is by means of a dry powder inhaler.
- 81. The method of claim 64 wherein delivery to the pulmonary system is by means of a metered dose inhaler.
RELATED APPLICATIONS
[0001] This application is a continuation of U.S. application Ser. No. 10/762,200, filed Jan. 21, 2004, which is a continuation of U.S. application Ser. No. 10/441,968, filed May 20, 2003, which is a continuation of U.S. application Ser. No. 09/877,734, filed Jun. 8, 2001, which is a continuation-in-part of U.S. application Ser. No. 09/665,252, filed on Sep. 19, 2000. The entire teachings of the above applications are incorporated herein by reference.
Continuations (3)
|
Number |
Date |
Country |
Parent |
10762200 |
Jan 2004 |
US |
Child |
10895577 |
Jul 2004 |
US |
Parent |
10441968 |
May 2003 |
US |
Child |
10762200 |
Jan 2004 |
US |
Parent |
09877734 |
Jun 2001 |
US |
Child |
10441968 |
May 2003 |
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
09665252 |
Sep 2000 |
US |
Child |
09877734 |
Jun 2001 |
US |